{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.54","value":"2.2"},{"groupId":"OG001","spread":"8.12","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.25","value":"3.3"},{"groupId":"OG001","spread":"10.34","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.28","value":"3.2"},{"groupId":"OG001","spread":"9.70","value":"2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.90","value":"2.3"},{"groupId":"OG001","spread":"8.67","value":"2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.54","value":"0.6"},{"groupId":"OG001","spread":"8.98","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.03","value":"1.8"},{"groupId":"OG001","spread":"6.97","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.84","value":"1.5"},{"groupId":"OG001","spread":"7.66","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"Cycle 15, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.11","value":"1.2"},{"groupId":"OG001","spread":"8.05","value":"2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.52","value":"0.7"},{"groupId":"OG001","spread":"9.32","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cycle 19, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.58","value":"1.6"},{"groupId":"OG001","spread":"7.66","value":"1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.08","value":"2.0"},{"groupId":"OG001","spread":"8.83","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.59","value":"2.0"},{"groupId":"OG001","spread":"8.73","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.19","value":"3.4"},{"groupId":"OG001","spread":"9.59","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Cycle 27, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.07","value":"3.9"},{"groupId":"OG001","spread":"8.51","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.43","value":"2.8"},{"groupId":"OG001","spread":"9.15","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 31, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.93","value":"2.0"},{"groupId":"OG001","spread":"9.17","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 33, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.27","value":"3.4"},{"groupId":"OG001","spread":"7.22","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Cycle 35, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.72","value":"4.1"},{"groupId":"OG001","spread":"11.72","value":"-3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 37, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.12","value":"3.6"},{"groupId":"OG001","spread":"2.82","value":"4.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 39, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.69","value":"3.3"},{"groupId":"OG001","spread":"6.90","value":"-0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 41, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.28","value":"5.3"},{"groupId":"OG001","spread":"1.91","value":"4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 43, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.99","value":"-0.3"},{"groupId":"OG001","spread":"0.28","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 45, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.30","value":"-2.5"},{"groupId":"OG001","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 47, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.95","value":"5.0"},{"groupId":"OG001","spread":"9.96","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Final visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \\[PROMIS\\] Cancer Fatigue Short Form \\[SF\\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"MEAN","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization; participants who have both baseline and post-baseline values are included in the analysis at each visit","reportingStatus":"POSTED","timeFrame":"Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment","title":"Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score","type":"SECONDARY","unitOfMeasure":"T-score"}